

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1-36. **(Previously Canceled)**

37. **(Currently Amended)** A method for treating Attention-Deficit Disorder or Attention-Deficit Hyperactivity Disorder in a patient, wherein the method comprises administering a pharmaceutically acceptable composition comprising ~~100 ng to 500 mg of~~ methylphenidate and a pharmaceutically acceptable carrier to said patient in a manner that achieves a substantially ascending methylphenidate plasma drug concentration over a time period of about 5.5 hours following said administration.

38-45. **(Previously Canceled)**

46. **(Previously Presented)** The method of claim 37 wherein said substantially ascending methylphenidate plasma drug concentration is over a time period of about 4 to about 5.5 hours.

47. **(Previously Presented)** The method of claim 37 wherein said substantially ascending methylphenidate plasma drug concentration is over a time period of about 5.5 to about 8 hours.

48. **(Previously Presented)** The method of claim 37 wherein said substantially ascending methylphenidate plasma drug concentration is over a time period of about 5.5 to about 9.5 hours.

49. **(Currently Amended)** A method for treating Attention-Deficit Disorder or Attention-Deficit Hyperactivity Disorder in a patient, wherein the method comprises administering a pharmaceutically acceptable composition comprising ~~100 ng to 500 mg of~~ methylphenidate and a pharmaceutically acceptable carrier to said patient in a manner that achieves a substantially ascending methylphenidate plasma drug concentration over a time period of about 8 hours following said administration.

50. **(Currently Amended)** A method for treating Attention-Deficit Disorder or Attention-Deficit Hyperactivity Disorder in a patient, wherein the method comprises administering a pharmaceutically acceptable composition comprising ~~100 ng to 500 mg of~~ methylphenidate and a pharmaceutically acceptable carrier to said patient in a manner that achieves a substantially ascending methylphenidate plasma drug concentration over a time period of about 9.5 hours following said administration.

51. **(New)** A method of claim 37 wherein said composition comprises about 14 mg of methylphenidate.

52. **(New)** A method of claim 37 wherein said composition comprises about 18 mg of methylphenidate.

53. **(New)** A method of claim 37 wherein said composition comprises about 36 mg of methylphenidate.

54. **(New)** A method of claim 37 wherein said composition comprises about 54 mg of methylphenidate.

55. **(New)** A method of claim 49 wherein said composition comprises about 14 mg of methylphenidate.

56. **(New)** A method of claim 49 wherein said composition comprises about 18 mg of methylphenidate.

57. **(New)** A method of claim 49 wherein said composition comprises about 36 mg of methylphenidate.

58. **(New)** A method of claim 49 wherein said composition comprises about 54 mg of methylphenidate.

59. (New) A method of claim 50 wherein said composition comprises about 14 mg of methylphenidate.

60. (New) A method of claim 50 wherein said composition comprises about 18 mg of methylphenidate.

61. (New) A method of claim 50 wherein said composition comprises about 36 mg of methylphenidate.

62. (New) A method of claim 50 wherein said composition comprises about 54 mg of methylphenidate.